Huemer Florian, Leisch Michael, Geisberger Roland, Zaborsky Nadja, Greil Richard
Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, 5020 Salzburg, Austria.
Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), 5020 Salzburg, Austria.
Pharmaceuticals (Basel). 2021 Jan 26;14(2):89. doi: 10.3390/ph14020089.
MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression by binding to complementary target regions on gene transcripts. Thus, miRNAs fine-tune gene expression profiles in a cell-type-specific manner and thereby regulate important cellular functions, such as cell growth, proliferation and cell death. MiRNAs are frequently dysregulated in cancer cells by several mechanisms, which significantly affect the course of the disease. In this review, we summarize the current knowledge on how dysregulated miRNAs contribute to cancer and how miRNAs can be exploited as predictive factors and therapeutic targets, particularly in regard to immune-checkpoint inhibitor therapies.
微小RNA(miRNA)是一类小的非编码RNA,通过与基因转录本上的互补靶区域结合来调节基因表达。因此,miRNA以细胞类型特异性的方式微调基因表达谱,从而调节重要的细胞功能,如细胞生长、增殖和细胞死亡。miRNA在癌细胞中经常通过多种机制发生失调,这显著影响疾病的进程。在本综述中,我们总结了目前关于失调的miRNA如何促成癌症以及miRNA如何被用作预测因子和治疗靶点的知识,特别是在免疫检查点抑制剂治疗方面。